TNF and rheumatoid arthritis: A number of studies, including a large nationwide Danish cohort study, have found that the CV risk associated with NSAID use in RA patients was significantly lower than in non-RA patients, possibly related to potential inflammatory mechanisms shared between RA and CV disease or better pain control and subsequent increase in mobility.42 Tofacitinib, a targeted synthetic DMARD that inhibits Janus Kinase (JAK), has been linked to higher risk of major adverse cardiovascular events (MACE) compared to anti-TNF therapy among patients with RA with a higher CV risk.